For example, either patients with Epstein–Barr virus infection and gastric cancer comorbidity, or patients with Epstein–Barr virus infection and non-Hodgkin lymphoma comorbidity, responded better to anti-PD-1 therapy than their Epstein–Barr virus negative counterparts [3, 41]. Here, PDCD1 is linked to non-Hodgkin lymphoma.